Corcept Therapeutics: President of Endocrinology Resigns; Successor Named

What Happened
Corcept Therapeutics filed an 8-K disclosing that Sean Maduck notified the board on September 22, 2026 that he will resign as President of Corcept Endocrinology effective October 1, 2026. The company said Mr. Maduck’s departure was not due to any disagreement with the company. A press release dated September 23, 2026 announced that Justin Gunn will succeed Mr. Maduck.

Key Details

• Resignation notice given: September 22, 2026; effective date: October 1, 2026.
• Consulting Services Agreement dated September 22, 2026 (effective Oct 1, 2026): initial term through September 30, 2027 unless earlier terminated.
• Consulting fee: $57,000 per month; either party may terminate with 30 days’ written notice.
• Previously awarded and outstanding stock options will continue to vest according to their original schedules during the consulting term.
• Company filed a press release (Exhibit 99.1) on September 23, 2026 announcing the retirement and successor.

Why It Matters
This is an executive-level change in Corcept’s commercial leadership for its endocrinology business. The consulting agreement and continued option vesting suggest the company seeks a transition with continuity and to retain Mr. Maduck’s expertise for up to a year while new leadership (Justin Gunn) assumes the role. Investors should note the recurring consulting expense ($57,000/month) and that the departure was expressly not due to disagreement with the company—facts that can inform assessments of management stability and succession planning.